Method and composition for angiogenesis inhibition
AssigneeUniversity of Southern California
InventorsPETER C. BROOKS, JINGSONG XU, ERIC PETITCLERC
Life of this patent
Estimating the term…
Abstract
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of the invention can target, for example, denatured collagens type-I, type-II, type-III, type-IV, type-V and combinations thereof. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. Antagonists include monoclonal antibodies referred to as HUI77, HUIV26, and XL313.
Claims59
An antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagen or collagens with substantially reduced affinity.
A method for screening for denatured collagen antagonists comprising:
- a) providing a putative antagonist;
- b) measuring said putative antagonist's first affinity for a denatured collagen selected from the group consisting of collagens types I, II, III, IV and V;
- c) measuring said putative antagonist's second affinity for a native collagen selected from the group consisting of collagens types I, II, III, IV and V, wherein said native collagen selected is the native form of the denatured collagen selected;
- d) selecting said putative antagonist as a denatured collagen antagonist if said second affinity is substantially less than said first affinity.
Dependencies are inferred from the claim text.